MedTrace Logo

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

NCT05868395 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-05-29

No results posted yet for this study

Summary

Polatuzumab, bendamustine and rituximab in patients with relapsed/ refractory mantle cell lymphoma

Conditions

  • Mantle-cell Lymphoma

Interventions

DRUG

Polatuzumab, bendamustin und rituximab

* Polatuzumab vedotin 1.8 mg/kg i.v. on day 2 of cycle 1, then on day 1 of each subsequent cycle * Bendamustine 90 mg/m2 i.v. day 2 \& 3 of cycle 1, then on day 1 \& 2 of each subsequent cycle * Rituximab 375 mg/m2 i.v. on day 1 of each cycle * Each cycle is 21 days long * Up to 6 cycles per patients planned

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Barbara Kiesewetter, MD · Medical University Vienna

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-02
Primary Completion
2027-05-24
Completion
2027-05-24

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05868395 on ClinicalTrials.gov